- Product
- A fierce battle between MDs & RPhs on Rx of ingredient names
- by Kang, Shin-Kook Nov 2, 2022 05:36am
- A fight between pharmaceutical organizations has begun over the prescription of ingredient names. Oh Yoo-kyung, head of the Ministry of Food and Drug Safety, made an excuse to actively agree to the prescription of the ingredient name, and complaints that have accumulated have been erupting. First, doctors are insisting that patients choose in-ho
- Product
- Benefit standards are the key to the migraine market
- by Whang, byung-woo Sep 16, 2022 05:52am
- Treatment options are also changing at clinical sites as CGRP (calcitonin gene-related peptide)-based migraine treatments are entering or about to enter the benefit range. However, given that the standard is high, it is expected that patients who receive actual benefits will be limited, so it is evaluated that the task to expand accessibility
- Product
- Change of insurance code for Tylenol ER 650mg
- by Kim JiEun Aug 31, 2022 05:40am
- Pharmacists say, "There's no inventory, but there's no point changing the billing code."Should we just fill up the existing medicine?" While the billing code for Tylenol ER, which ran out of stock at pharmacies, has changed, the company's notice itself has become meaningless at pharmacies. According to Johnson & Johnson and the pharmacy in Ko
- Product
- There are about 2,300 pharmacies dedicated to COVID-19
- by Jung, Heung-Jun Aug 24, 2022 05:55am
- Increase in active prescription recommendations of the Korea Medical Association, and short expiration date also affects prescription volume. The number of pharmacies in charge of COVID-19 treatments has more than doubled in a month. The number of pharmacies in charge increased from 996 on the 11th of last month to 2,314 on the 19th of this m
- Product
- Settlement of Xarelto price difference
- by Jung, Heung-Jun Aug 18, 2022 05:47am
- Some wholesalers are complaining at pharmacies as they demand that Xarelto, which will be lowered in drug prices, be returned by this week. This is because if the physical return is closed a week ago, there is no inventory to be prepared next week. In the case of Xarelto, wholesale companies seem to avoid returning on paper because the drug p
- Product
- H. pylori with 50% prevalence requires active examination/tx
- by jung, sae-im Aug 7, 2022 11:29pm
- Helicobacter pylori is a bacteria that causes digestive diseases such as acute gastritis, chronic gastritis, gastric ulcer, duodenal ulcer, gastric lymphoma, and gastric cancer, and is defined by the World Health Organization as a first-class carcinogen. As half of the nation's population is evaluated as Helicobacter infections, the importance o
- Product
- Nearly 100,000 COVID-19 confirmed cases
- by Kim JiEun Jul 28, 2022 05:54am
- Society has no guidelines despite the spread of the disease. As COVID-19 spreads again, face-to-face administration at pharmacies is also increasing significantly. Individual pharmacies are trying to quarantine, but confusion is also detected as it goes against social sentiment. On the 26th, the Central Disease Control Headquarters of the Kor
- Product
- Medical institutions earned ₩7 trillion with COVID-19
- by Kang, Shin-Kook Jul 27, 2022 05:50am
- A whole &8361;7.1028 trillion was spent on medical fees for COVID-19-related matters over the past two and a half years since the pandemic first hit Korea. The medical staff, acclaimed for their efforts in the pandemic, have also earned much for their incredible amount of hard work. In the same period, pharmacies have only earned around &83
- Product
- MOHW meets Doctornow to listen to platform guidelines
- by Kim JiEun Jul 27, 2022 05:49am
- The timing of the announcement of the guidelines for the non-face-to-face treatment brokerage platform announced by the government is later than expected. In addition to the opinions of the medical and pharmaceutical sectors, the government's intention to reflect some of the opinions of platform companies is read. It has been confirmed that t
- Product
- Sell Saxenda directly after non-face-to-face treatment?
- by Jung, Heung-Jun Jul 10, 2022 03:31pm
- Can hospitals sell Saxenda, known as diet injections, directly to patients after non-face-to-face treatment? It is an expensive drug worth more than 100,000 won per unit and there is a high demand for purchase, so it is not prescribed for outpatients. The problem is that some hospitals sell and deliver directly to patients even in non-face-to
